Basilea Pharmaceutica AG (BSLN) - Total Assets
Based on the latest financial reports, Basilea Pharmaceutica AG (BSLN) holds total assets worth CHF282.00 Million CHF (≈ $356.52 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BSLN debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Basilea Pharmaceutica AG - Total Assets Trend (2002–2025)
This chart illustrates how Basilea Pharmaceutica AG's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Basilea Pharmaceutica AG for net asset value and shareholders' equity analysis.
Basilea Pharmaceutica AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Basilea Pharmaceutica AG's total assets of CHF282.00 Million consist of 89.3% current assets and 10.7% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF132.70 Million | 10.5% |
| Accounts Receivable | CHF63.28 Million | 22.4% |
| Inventory | CHF21.56 Million | 7.6% |
| Property, Plant & Equipment | CHF18.15 Million | 6.4% |
| Intangible Assets | CHF371.00K | 0.1% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Basilea Pharmaceutica AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BSLN market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Basilea Pharmaceutica AG's current assets represent 89.3% of total assets in 2025, an increase from 79.7% in 2002.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2025, down from 27.3% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is cash and equivalents at 10.5% of total assets.
Basilea Pharmaceutica AG Competitors by Total Assets
Key competitors of Basilea Pharmaceutica AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
Basilea Pharmaceutica AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.11 | 4.85 | 4.46 |
| Quick Ratio | 4.68 | 4.16 | 4.03 |
| Cash Ratio | 3.25 | 2.65 | 1.21 |
| Working Capital | CHF202.51 Million | CHF175.35 Million | CHF173.37 Million |
Basilea Pharmaceutica AG - Advanced Valuation Insights
This section examines the relationship between Basilea Pharmaceutica AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.23 |
| Latest Market Cap to Assets Ratio | 2.43 |
| Asset Growth Rate (YoY) | 9.4% |
| Total Assets | CHF282.00 Million |
| Market Capitalization | $686.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Basilea Pharmaceutica AG's assets at a significant premium (2.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Basilea Pharmaceutica AG's assets grew by 9.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Basilea Pharmaceutica AG (2002–2025)
The table below shows the annual total assets of Basilea Pharmaceutica AG from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF282.00 Million ≈ $356.52 Million |
+9.40% |
| 2024-12-31 | CHF257.76 Million ≈ $325.88 Million |
+48.75% |
| 2023-12-31 | CHF173.29 Million ≈ $219.08 Million |
-21.53% |
| 2022-12-31 | CHF220.85 Million ≈ $279.21 Million |
-10.68% |
| 2021-12-31 | CHF247.27 Million ≈ $312.61 Million |
+7.60% |
| 2020-12-31 | CHF229.79 Million ≈ $290.52 Million |
+3.76% |
| 2019-12-31 | CHF221.47 Million ≈ $279.99 Million |
-21.40% |
| 2018-12-31 | CHF281.75 Million ≈ $356.21 Million |
-19.77% |
| 2017-12-31 | CHF351.17 Million ≈ $443.97 Million |
+7.14% |
| 2016-12-31 | CHF327.76 Million ≈ $414.37 Million |
-17.80% |
| 2015-12-31 | CHF398.74 Million ≈ $504.11 Million |
+54.92% |
| 2014-12-31 | CHF257.38 Million ≈ $325.40 Million |
-14.14% |
| 2013-12-31 | CHF299.76 Million ≈ $378.97 Million |
-20.14% |
| 2012-12-31 | CHF375.34 Million ≈ $474.54 Million |
+58.31% |
| 2011-12-31 | CHF237.09 Million ≈ $299.75 Million |
-25.10% |
| 2010-12-31 | CHF316.54 Million ≈ $400.20 Million |
+53.21% |
| 2009-12-31 | CHF206.61 Million ≈ $261.21 Million |
-37.03% |
| 2008-12-31 | CHF328.13 Million ≈ $414.84 Million |
-28.89% |
| 2007-12-31 | CHF461.45 Million ≈ $583.40 Million |
+127.22% |
| 2006-12-31 | CHF203.09 Million ≈ $256.76 Million |
-20.53% |
| 2005-12-31 | CHF255.56 Million ≈ $323.10 Million |
+10.74% |
| 2004-12-31 | CHF230.78 Million ≈ $291.77 Million |
+115.64% |
| 2003-12-31 | CHF107.02 Million ≈ $135.30 Million |
-28.90% |
| 2002-12-31 | CHF150.51 Million ≈ $190.29 Million |
-- |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more